Gary R Lichtenstein

List of Publications by Citations

Source: https://exaly.com/author-pdf/3311701/gary-r-lichtenstein-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69 papers	5,273 citations	24 h-index	72 g-index
79 ext. papers	6,087 ext. citations	3.1 avg, IF	5.76 L-index

#	Paper	IF	Citations
69	Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. *Clinical Gastroenterology and Hepatology*, **2006**, 4, 621-30	6.9	724
68	Management of Crohn's disease in adults. *American Journal of Gastroenterology*, **2009**, 104, 465-83; quiz 464, 484	0.7	691
67	ACG Clinical Guideline: Management of Crohn's Disease in Adults. *American Journal of Gastroenterology*, **2018**, 113, 481-517	0.7	518
66	Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. *American Journal of Gastroenterology*, **2012**, 107, 1409-22	0.7	513
65	Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. *Gastroenterology*, **2005**, 128, 862-9	13.3	485
64	ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. *American Journal of Gastroenterology*, **2017**, 112, 241-258	0.7	241
63	Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 95-102	6.9	229
62	Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. *American Journal of Gastroenterology*, **2004**, 99, 91-6	0.7	216
61	Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. *American Journal of Gastroenterology*, **2006**, 101, 1030-8	0.7	174
60	Importance of mucosal healing in ulcerative colitis. *Inflammatory Bowel Diseases*, **2010**, 16, 338-46	4.5	161
59	A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. *American Journal of Gastroenterology*, **2012**, 107, 1051-63	0.7	153
58	Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT Registry. *American Journal of Gastroenterology*, **2014**, 109, 212-23	0.7	130
57	Infliximab improves quality of life in patients with Crohn's disease. *Inflammatory Bowel Diseases*, **2002**, 8, 237-43	4.5	114
56	Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 600-9	6.9	91
55	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. *Journal of Crohn's and Colitis*, **2018**, 12, 1158-1169	1.5	70
54	Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. *Inflammatory Bowel Diseases*, **2011**, 17, 2488-96	4.5	65
53	Prevention and treatment of osteoporosis in inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2006**, 12, 797-813	4.5	62

52	Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. *Therapeutic Advances in Gastroenterology*, **2013**, 6, 269-93	4.7	58
51	Fatal hyperammonemia after orthotopic lung transplantation. *Annals of Internal Medicine*, **2000**, 132, 283-7	8	56
50	Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. *Inflammatory Bowel Diseases*, **2018**, 24, 490-501	4.5	53
49	Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 31-40	6.1	48
48	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. *Journal of Crohnts and Colitis*, **2015**, 9, 607-16	1.5	40
47	Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. *American Journal of Gastroenterology*, **2018**, 113, 1678-1688	0.7	34
46	Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 889-897.e10	6.9	25
45	Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. *Journal of Crohnts and Colitis*, **2015**, 9, 738-46	1.5	23
44	Ischemic colitis associated with decongestant use. *Annals of Internal Medicine*, **2000**, 132, 682	8	21
43	Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. *Digestive Diseases and Sciences*, **2017**, 62, 1354-1361	4	20
42	Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease. *Inflammatory Bowel Diseases*, **2001**, 7 Suppl 1, S23-9	4.5	20
41	Efficacy and safety of adalimumab in Crohn's disease. *Therapeutic Advances in Gastroenterology*, **2008**, 1, 43-50	4.7	19
40	Is infliximab effective for induction of remission in patients with ulcerative colitis?. *Inflammatory Bowel Diseases*, **2001**, 7, 89-93	4.5	18
39	Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals. *Journal of Managed Care & Specialty Pharmacy*, **2019**, 25, 904-912	1.9	16
38	Evaluation of bone mineral density in inflammatory bowel disease: current safety focus. *American Journal of Gastroenterology*, **2003**, 98, S24-30	0.7	15
37	Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy. *American Journal of Gastroenterology*, **2005**, 100, 1433-5	0.7	13
36	Mimics of Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2018**, 24, 2315-2321	4.5	13
35	Assessing Drug Treatment Preferences of Patients with Crohn Disease. *Patient*, **2010**, 3, 113-123	3.7	12

34	Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic: Two challenging and informative clinical cases. *Head and Neck*, **2020**, 42, 1131-1136	4.2	11
33	Hospitalization Outcomes for Inflammatory Bowel Disease in Teaching vs Nonteaching Hospitals. *Inflammatory Bowel Diseases*, **2019**, 25, 1974-1982	4.5	9
32	Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy. *American Journal of Gastroenterology*, **2020**, 115, 687-688	0.7	9
31	Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. *Current Treatment Options in Gastroenterology*, **2018**, 16, 147-164	2.5	9
30	Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron. *Digestive Diseases and Sciences*, **2018**, 63, 3009-3019	4	9
29	Exposure to Intravenous Opioids Is Associated With Future Exposure to Opioids in Hospitalized Patients With Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2269-2278.e3	6.9	9
28	A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis. *Inflammatory Bowel Diseases*, **2019**, 25, 1550-1558	4.5	8
27	Evaluation and Detection of Dysplasia in IBD: the Role of Chromoendoscopy and Enhanced Imaging Techniques. *Current Treatment Options in Gastroenterology*, **2016**, 14, 73-82	2.5	7
26	Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan Administrative Claims Database With Tofacitinib Trial Data. *Inflammatory Bowel Diseases*, **2021**, 27, 1394-1408	4.5	7
25	The TREAT Registry: Evolution of Knowledge From 1999 to 2017: Lessons Learned. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1319-1321	6.9	4
24	Approach to the Patient with Mild Crohn's Disease: a 2016 Update. *Current Gastroenterology Reports*, **2016**, 18, 50	5	4
23	Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. *Inflammatory Bowel Diseases*, **2017**, 24, 217-226	4.5	3
22	Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. *Digestive Diseases and Sciences*, **2016**, 61, 221-9	4	3
21	Biliary Tract Dysmotility. *Current Treatment Options in Gastroenterology*, **1998**, 1, 27-34	2.5	3
20	Biosimilars in Inflammatory Bowel Disease. *American Journal of Gastroenterology*, **2021**, 116, 45-56	0.7	3
19	Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. *Gastroenterology and Hepatology*, **2015**, 11, 1-16	0.7	3
18	Preadmission Cannabis Use Is Positively Correlated With Inpatient Opioid Dose Exposure in Hospitalized Patients With Inflammatory Bowel Diseases. *Inflammatory Bowel Diseases*, **2021**, 27, 500-506	4.5	3
17	Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease. *Clinical Medicine Insights Gastroenterology*, **2012**, 5, 11-21		2

16	Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. *Reviews in Gastroenterological Disorders*, **2008**, 8, 21-30; quiz 31-2		2
15	Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis. *Digestive Diseases and Sciences*, **2019**, 64, 1138-1141	4	1
14	Precision Medicine: Predicting Disease Course in Patients with Inflammatory Bowel Disease. *Current Treatment Options in Gastroenterology*, **2020**, 18, 574-588	2.5	
13	Introduction to Clinical Practice Update Committee Articles. *Gastroenterology*, **2016**, 151, 45	13.3	
12	Crohn Disease **2010**, 225-235		
11	Once-Daily MMX Mesalamine in the Management of Ulcerative colitis. *Clinical Medicine Gastroenterology*, **2011**, 4, CGast.S4276		
10	Abdominal Abscesses and Gastrointestinal Fistula **2010**, 376-381		
9	A review of standard and novel therapies in Crohn disease. *Expert Opinion on Therapeutic Patents*, **2000**, 10, 1021-1033	6.8	
8	Highlights From the 2020 Virtual Advances in Inflammatory Bowel Diseases Conference: Commentary. *Gastroenterology and Hepatology*, **2021**, 17, 15-18	0.7	
7	Response to Chamberlin and Borody. *American Journal of Gastroenterology*, **2019**, 114, 171-174	0.7	
6	Does Anti-TNF Therapy Increase the Risk of Complications of Surgery?186-191		
5	Meta-Analysis Of Overall Risk Of Lymphoma In Patients With Inflammatory Bowel Disease On Thiopurine Therapy With Inclusion Of New Nationwide Population Based Studies: Differences Between Referral Center Studies and Population Based Studies. *Blood*, **2013**, 122, 4276-4276	2.2	
4	Response to Ribaldone. *American Journal of Gastroenterology*, **2019**, 114, 826-827	0.7	
3	Response to Chapman and Jones. *American Journal of Gastroenterology*, **2019**, 114, 828	0.7	
2	The Impact of Introducing Patient-Reported Inflammatory Bowel Disease Symptoms via Electronic Survey on Clinic Visit Length, Patient and Provider Satisfaction, and the Environment Microbiome. *Inflammatory Bowel Diseases*, **2021**, 27, 746-750	4.5	
1	Increased Lifetime Risk of Intestinal Complications and Extraintestinal Manifestations in Crohn's Disease and Ulcerative Colitis.. *Gastroenterology and Hepatology*, **2022**, 18, 32-43	0.7	